This is a prospective, multi-center, single arm, non-randomized study to define safety and efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective Performance goals. A maximum of 200 patients at up to 45 centers worldwide will be enrolled. Thirty (30) feasibility patients will be enrolled at approximately 7-10 centers and 170 pivotal patients will be enrolled at approximately 45 centers worldwide. The follow-up period is 36 months.
The objective of this prospective study is to assess the safety and efficacy of the Veniti Vici™ Venous Stent System in achieving patency of the target venous lesion in patients who present with clinically significant chronic non-malignant obstruction of the iliofemoral venous outflow tract.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Abrazo Arizona Heart Hospital
Phoenix, Arizona, United States
Healthfinity PLCC
Scottsdale, Arizona, United States
Arkansas Site Management Services, LLC
Little Rock, Arkansas, United States
St. Joseph Hospital
Orange, California, United States
Radiology Imaging Associates
Englewood, Colorado, United States
Vascular Breakthroughs
Darien, Connecticut, United States
Midwest Cardiovascular Foundation
Davenport, Iowa, United States
Imperial Health, LLP
Lake Charles, Louisiana, United States
Michigan Vascular Center
Flint, Michigan, United States
NYU School of Medicine
New York, New York, United States
...and 14 more locations
Number of Participants With Major Adverse Events (MAE)
The primary safety endpoint for this study will be a composite endpoint of any major adverse event (MAE) within 30 days, as adjudicated by a Clinical Events Committee.
Time frame: 30 days
Percentage of Participants That Demonstrated Primary Patency
The primary effectiveness endpoint is the primary patency rate at 12 months post-intervention, defined as freedom from occlusion by thrombosis, freedom from surgical or endovascular intervention on target vessel which are found to have re-stenosis or stent occlusion to maintain patency, and freedom from in-stent stenosis more than 50% by venogram.
Time frame: 12 months post-intervention
Number of Participants With Improvement in Venous Clinical Severity Score (VCSS)
The secondary effectiveness endpoint for this study will be a binary response variable based on an improvement in Venous Clinical Severity Score (VCSS) by at least 50% at 12 months post-intervention. VCSS measures 10 clinical attributes of venous disease (Pain, Varicose Veins, Venous Edema, Skin Pigmentation, Inflammation, Induration, No. Active Ulcers, Active Ulcer Size, Ulcer Duration and Compression Therapy) on a scale of 0 - 3 (Absent 0, Mild 1, Moderate 2, and Severe 3).
Time frame: 12 months post-intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.